Targeted therapy for gastrointestinal stromal tumors: current status and future perspectives

@article{Papaetis2010TargetedTF,
  title={Targeted therapy for gastrointestinal stromal tumors: current status and future perspectives},
  author={Georgios S. Papaetis and Konstantinos Syrigos},
  journal={Cancer and Metastasis Reviews},
  year={2010},
  volume={29},
  pages={151-170}
}
Gastrointestinal stromal tumors (GISTs) present 80% of gastrointestinal tract mesenchymal tumors, with systemic chemotherapy and radiotherapy being unable to improve survival of patients with advanced disease. The identification of activating mutations in either KIT cell surface growth factor receptor or platelet-derived growth factor receptor alpha, which lead to ligand-independent signal transduction, paved the way for the development of novel agents that selectively inhibit key molecular… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 171 references

Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: A phase I study

  • A. T. van Oosterom, I. Judson, J. Verweij, S. Stroobants, E. Donato di Paola, S Dimitrijevic
  • 2001
Highly Influential
4 Excerpts

Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: A phase I study

  • A. T. van Oosterom, I. Judson, J. Verweij, S. Stroobants, E. Donato di Paola, S Dimitrijevic
  • 2001
Highly Influential
4 Excerpts